Current Appointments & Affiliations
Research Scientist
Pharmacology & Cancer Biology,
Basic Science Departments
Recent Publications
The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.
Journal Article Mol Cancer Ther · December 12, 2025 Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER) positive, HER2 negative (ER+/HER2-) breast cancer; however, de novo or acquired resistance remains a major clinical challenge. Upon progression, many of the cancers cont ... Full text Link to item CiteData from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
Other · November 24, 2025 <div>Abstract<p>Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains hi ... Full text CiteSupplementary Video 4 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
Other · November 24, 2025 <p>Supplementary Video 4</p> ... Full text CiteRecent Grants
Manipulating normal estrogen physiology as a therapeutic approach in cancer
ResearchResearch Scientist · Awarded by National Institutes of Health · 2023 - 2028Development of Novel ERRalpha Antagonists as Breast Cancer Therapeutics
ResearchResearch Scientist · Awarded by National Institutes of Health · 2022 - 2024Evaluation of the efficacy of a combined regimen including an ER targeted therapy and ICB
ResearchResearch Scientist · Awarded by Sermonix Pharmaceuticals · 2023 - 2024View All Grants